127308-82-1

Basic information

• Product Name: ZAMIFENACIN
• Synonyms: Piperidine,1-[2-(1,3-benzodioxol-5-yl)ethyl]-3-(diphenylmethoxy)-, (R)-; (+)-Zamifenacine;UK 76654; Zamifenacin
• CAS NO: 127308-82-1
• Molecular Formula: C27H29NO3
• Molecular Weight: 415.52406
• Mol File: 127308-82-1.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 532.5°Cat760mmHg
• Flash Point: 145.6°C
• Appearance: /
• Density: 1.2g/cm³
• Vapor Pressure: 2.04E-11mmHg at 25°C
• Refractive Index: 1.633
• CAS DataBase Reference: ZAMIFENACIN(CAS DataBase Reference)
• NIST Chemistry Reference: ZAMIFENACIN(127308-82-1)
• EPA Substance Registry System: ZAMIFENACIN(127308-82-1)

Safety Data

• Hazardous Substances Data: 127308-82-1(Hazardous Substances Data)

Usage

Originator

Zamifenacin,Sumitomo Industries

Manufacturing Process

(3R)-Diphenylmethoxy-1-(3,4-methylenedioxyphenethyl)piperidine: A mixture of (3R)-diphenylmethoxypiperidine (2.67 g), 3,4- methylenedioxyphenethyl bromide (2.29 g), sodium carbonate (2.10 g) and sodium iodide (0.25 g) in acetonitrile (50 ml) was heated under reflux for 68 hours, diluted with ethyl acetate and water, and the layers were separated. The organic layer was washed with water, dried over magnesium sulfate and evaporated. The residue was purified by chromatography on silica (50 g) using methylene chloride containing 0-5% methanol as the eluant. The title compound (zamifenacin) was obtained as a colourless solid after recrystallisation from hexane (1.25 g, 78%), MP: 52°-55°C, [α] D 25 = +22.5° (c 1.5 in ethanol).The starting compounds were prepared next way: 1. (3R)-Diphenylmethoxypiperidine:A solution of (3R)-hydroxypiperidinium (1S)-camphor-10-sulphonate prepared from (3R,S)-hydroxypiperidine by the method of B. Ringdahl, U. F. W. Ohnsorge and J. C. Craig, [J. Chem. Soc. Perkin II, (1981), 697], [α] D 25 =+23.1° (c 1.5 in 50% aqueous ethanol; (1 mole-equivalent), benzhydrol (1mole-equivalent) and p-toluenesulphonic acid monohydrate (1 mole-equivalent) in toluene (600 ml) was heated under reflux for four hours using a Dean-Stark apparatus to remove the water formed. The mixture was then partitioned between 2 M aqueous sodium hydroxide solution and ethyl acetate and the organic layer was washed with water and evaporated. The residue was partitioned between ether and 10% aqueous citric acid and the acidic layer was washed with ether, basified with excess solid sodium carbonate and extracted into ether. The organic layer was washed with water, dried over magnesium sulfate and evaporated to give the title compound a colourless oil (2.7 g, 50%), [α] D 25 =+3.3° (c 1.5 in ethanol), which was characterized by its 1 H-NMR spectrum.2. 3,4-Methylenedioxyphenethyl alcohol:3,4-Methylenedioxyphenylacetic acid (18.0 g) was added portion wise over 30 minutes to a stirred, ice-cooled suspension of lithium aluminium hydride (4.0 g) in ether (400 ml) and the mixture was stirred at temperature for two hours, quenched by the cautious addition of saturated aqueous ammonium chloride solution and filtered. The filtrate was washed with 10% aqueous sodium carbonate solution, dried over magnesium sulfate and evaporated to give the title compound as a pale yellow oil (15.01 g, 90%), which was characterized by its 1 H-NMR spectrum.3. 3,4-Methylenedioxyphenethyl bromide:A solution of phosphorus tribromide (8.1 g) in carbon tetrachloride (50 ml) was added dropwise over 30 minutes to a stirred solution of 3,4- methylenedioxyphenethyl alcohol (15.0 g) in carbon tetrachloride (200 ml) and the mixture was heated under reflux for 3 hours, washed sequentially with water (twice), 5 M aqueous sodium hydroxide solution and water, dried over magnesium sulfate and evaporated. The residue was purified by chromatography on silica (100 g) using carbon tetrachloride as the eluant. Appropriate fractions were combined and evaporated to give the 3,4- methylenedioxyphenethyl bromide as a pale yellow oil (8.3 g, 40%), which was characterized by its 1 H-NMR spectrum.Zamifenacin may be also synthesized from L-proline methyl ester in 4 steps an overall yield of 20% by using a ring enlargement of L-proline derivative.

Therapeutic Function

Antimuscarinic

InChI:InChI=1/C27H29NO3/c1-3-8-22(9-4-1)27(23-10-5-2-6-11-23)31-24-12-7-16-28(19-24)17-15-21-13-14-25-26(18-21)30-20-29-25/h1-6,8-11,13-14,18,24,27H,7,12,15-17,19-20H2/t24-/m1/s1